New Hampshire 2024 Regular Session

New Hampshire House Bill HB1349

Introduced
12/6/23  
Refer
12/6/23  
Report Pass
2/23/24  
Engrossed
3/13/24  
Refer
3/13/24  
Report Pass
5/1/24  
Report Pass
5/15/24  
Enrolled
6/27/24  
Chaptered
7/22/24  

Caption

Relative to generalized anxiety disorder as a qualifying condition for the therapeutic cannabis program.

Impact

The introduction of HB 1349 could have important implications for state laws regarding access to medical cannabis. By recognizing generalized anxiety disorder as a qualifying condition, the bill contributes to the evolving landscape of cannabis legislation in New Hampshire. The Department of Health and Human Services anticipates that the bill may increase the number of applicants for the Therapeutic Cannabis Program, thereby generating additional application fee revenue. Although the estimated increase appears modest, it could still represent a meaningful shift in law and public health policy, potentially benefiting hundreds of individuals struggling with anxiety.

Summary

House Bill 1349, known as the Act Relative to Generalized Anxiety Disorder as a Qualifying Condition for the Therapeutic Cannabis Program, aims to broaden the scope of conditions eligible for medical cannabis use by including generalized anxiety disorder. This legislative change is expected to allow individuals suffering from this mental health condition to access therapeutic cannabis, thus enhancing treatment options for a significant patient population. The inclusion of anxiety disorders acknowledges the growing recognition of mental health issues and the role that cannabis may play in alleviating symptoms associated with anxiety disorders.

Contention

While the bill appears to have broad support among legislators and advocacy groups, discussions surrounding its implementation may raise concerns about the adequacy of resources required to manage an influx of new applications. Additionally, the bill's impact on cannabis-related revenue and its self-funding mechanism under RSA 126-X could be points of contention as stakeholders consider the administrative and operational implications of onboarding a higher number of participants. The absence of provisions for additional staffing could lead to discussions on operational capacity and the sustainability of the program as it expands.

Companion Bills

No companion bills found.

Previously Filed As

NH SB2745

Mississippi Medical Cannabis Act; amend to add anxiety and sleep disorders as debilitating medical conditions.

NH SB264

Relative to the therapeutic cannabis program.

NH HB190

Relative to therapeutic cannabis possession limits.

NH HB51

Relative to hemp-derived cannabinoids and the definition of cannabis in therapeutic cannabis.

NH HB53

Permitting qualifying patients and designated caregivers to cultivate cannabis for therapeutic use.

NH HB380

Relative to penalties for criminal violations of the therapeutic use of cannabis.

NH HB205

Relative to exempting veterans from certification fees for therapeutic cannabis.

NH SB400

relative to duties and reporting requirements of the therapeutic cannabis medical oversight board.

NH HB386

AN ACT relating to coverage for perinatal mood and anxiety disorders screenings.

NH SB650

relative to use of cannabis products for therapeutic purposes by alternative treatment centers.

Similar Bills

CA AB2442

Peptides.

AR HB1218

To Create Licensure For Therapeutic Recreation Specialists; And To Create The Therapeutic Recreation Practice Act.

CA SB476

Short-term residential therapeutic programs.

TX HB3211

Relating to vision care benefits, including participation of optometrists and therapeutic optometrists in vision care or managed care plans.

CA AB448

California Health Facilities Financing Authority Act: nondesignated hospitals: loan repayment.

CA SB1109

Short-term residential therapeutic programs.

MA H377

Relative to growing resources to optimize the utilization of group therapeutic care

US SB4220

Veterans Health Administration Novel Therapeutics Preparedness Act